HEMISPHERX BIOPHARMA, INC. (NYSEMKT:HEB) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On March 31, 2017, Hemispherx Biopharma, Inc. (the Company) filed
its annual report on Form 10-K for the year-ended December 31,
2016 and, thereafter, issued a press release announcing its
financial results for the fourth quarter and year ended 2016. A
copy of the press release is furnished as Exhibit 99.1 hereto and
is incorporated herein by reference.
As noted in the press release, the Company will host a conference
call at 11:00 a.m. Eastern Daylight Time (EDT) on Friday, April
7, 2017 to provide a general business update. Hemispherx will
respond to various stockholder questions submitted prior to the
call.
Conference Call Information
| Date: | Friday, April 7, 2017 |
| Time: | 11:00 AM EDT |
| Dial-in numbers: | 800-346-7359 (domestic) |
| 973-528-0008 (international) | |
| Conference number: | |
| Questions: |
[email protected] by 65:00 p.m. EDT on Wednesday, April 5, 2017 |
| http://ir.hemispherx.net/Events_Presentations |
Item 7.01 Regulation FD Disclosure.
The information disclosed in Item 2.02 above is incorporated into
this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished
under Item 2.02, Results of Operations and Financial Condition,
Item 7.01, Regulation FD Disclosure and Item 9.01 Financial
Statements and Exhibits of Form 8-K. As such, the information
(including the exhibit) herein shall not be deemed to be filed
for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, nor shall it be incorporated by
reference into a filing under the Securities Act of 1933, as
amended, or the Exchange Act, regardless of any general
incorporation language in such filing, except as shall be
expressly set forth by specific reference in such a filing. This
Current Report (including the exhibit hereto) will not be deemed
an admission as to the materiality of any information required to
be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated March 31, 2017
About HEMISPHERX BIOPHARMA, INC. (NYSEMKT:HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company’s products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration. HEMISPHERX BIOPHARMA, INC. (NYSEMKT:HEB) Recent Trading Information
HEMISPHERX BIOPHARMA, INC. (NYSEMKT:HEB) closed its last trading session up +0.013 at 0.558 with 196,095 shares trading hands.
